Details

From biomarker discovery to clinical applications of metabolomics in glioblastoma
ID Šamec, Neja (Author), ID Krapež, Gloria (Author), ID Skubic, Cene (Author), ID Jovchevska, Ivana (Author), ID Videtič Paska, Alja (Author)

.pdfPDF - Presentation file, Download (2,23 MB)
MD5: 78363708F949437867BA396ADFE64E68
URLURL - Source URL, Visit https://www.mdpi.com/2218-1989/15/5/295 This link opens in a new window

Abstract
Background/Objectives: In recent years, interest in studying changes in cancer metabolites has resulted in significant advances in the metabolomics field. Glioblastoma remains the most aggressive and lethal brain malignancy, which presents with notable metabolic reprogramming. Methods: We performed literature research from the PubMed database and considered research articles focused on the key metabolic pathways altered in glioblastoma (e.g., glycolysis, lipid metabolism, TCA cycle), the role of oncometabolites and metabolic plasticity, and the differential expression of metabolites in glioblastoma. Currently used metabolomics approaches can be either targeted, focusing on specific metabolites and pathways, or untargeted, which involves data-driven exploration of the metabolome and also results in the identification of new metabolites. Data processing and analysis is of great importance and can be improved with the integration of machine learning approaches for metabolite identification. Results: Changes in α/β-glucose, lactate, choline, and 2-hydroxyglutarate were detected in glioblastoma compared with non-tumor tissues. Different metabolites such as fumarate, tyrosine, and leucine, as well as citric acid, isocitric acid, shikimate, and GABA were detected in blood and CSF, respectively. Conclusions: Although promising new technological and bioinformatic approaches help us understand glioblastoma better, challenges associated with biomarker availability, tumor heterogeneity, interpatient variability, standardization, and reproducibility still remain. Metabolomics research, either alone or combined with genomics or proteomics (i.e., multiomics) in glioblastoma, can lead to biomarker identification, tracking of metabolic therapy response, discovery of novel metabolites and pathways, and identification of potential therapeutic targets.

Language:English
Keywords:omics, metabolome, multiomic integration, tumor metabolic reprogramming, biomarker, diagnosis, therapy, precision oncology
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:24 str.
Numbering:Vol. 15, no. 5, art. 295
PID:20.500.12556/RUL-178219 This link opens in a new window
UDC:577.2
ISSN on article:2218-1989
DOI:10.3390/metabo15050295 This link opens in a new window
COBISS.SI-ID:235300099 This link opens in a new window
Publication date in RUL:21.01.2026
Views:345
Downloads:160
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Metabolites
Shortened title:Metabolites
Publisher:MDPI
ISSN:2218-1989
COBISS.SI-ID:523274009 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:omike, metabolom, multiomska integracija, presnovno reprogramiranje tumorja, biološki označevalec, dignoza, terapija, precizna onkologija

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0390
Name:Funkcijska genomika in biotehnologija za zdravje

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young researchers

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back